A Study of LY3871801 in Healthy Asian and Non-Asian Participants

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-08-09

Study Completion Date

2023-10-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The main purpose of this study is to evaluate the safety and tolerability of LY3871801 when administered as multiple doses in Healthy Asian and Non-Asian Participants. The study will also evaluate the amount of LY3871801 that gets into the blood stream and how long it takes the body to get rid of it in these participants. The study will be conducted in two parts (A \& B). The study will last up to approximately 24 days excluding the screening period.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study of LY3873862 in Healthy Participants

NCT05492201

Healthy

COMPLETED PHASE1

A Study of LY3540378 in Healthy Participants

NCT04768855

Healthy

COMPLETED PHASE1

A Study of LY3471851 in Healthy Participants

NCT04133116

Healthy

COMPLETED PHASE1

A Study of LY3871801 in Healthy Participants

NCT05222399

Healthy

COMPLETED PHASE1

A Study of LY3473329 in Healthy Japanese Participants

NCT05038787

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

LY3871801 (Part A)

LY3871801 administered orally in Japanese and Non-Asian Participants.

Group Type EXPERIMENTAL

LY3871801

Intervention Type DRUG

Administered orally.

Placebo (Part A)

Placebo administered orally in Japanese and Non-Asian Participants.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally.

LY3871801 (Part B)

LY3871801 administered orally in Chinese Participants.

Group Type EXPERIMENTAL

LY3871801

Intervention Type DRUG

Administered orally.

Placebo (Part B)

Placebo administered orally in Chinese Participants.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Administered orally.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

LY3871801

Administered orally.

Intervention Type DRUG

Placebo

Administered orally.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Are Japanese, Chinese, or Non-Asian participants who are overtly healthy as determined by medical evaluation
* Have body weight of \>/= 45 kilograms (kg) \& a body mass index (BMI) in the range of 18.5 to 29.5 kilogram per square meter (kg/m²). The Japanese participants must have a body weight of 45 to 85 kg and a BMI of 18.0 to 29.5 kg/m²

Exclusion Criteria

* Have known allergies to LY3871801, related compounds, or any components of the formulation, or history of significant atopy
* Have a significant history of or current cardiovascular or heart failure (based on New York Heart Association Functional Classification), respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs
* Are females who are lactating or have a positive pregnancy test at screening or Day 1
* Positive for drug or alcohol screen at screening or Day -1
* Smoke more than 10 cigarettes per day

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes